We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+7.98%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.25B
AUM Growth
-$1.7B
Cap. Flow
-$2.08B
Cap. Flow %
-33.31%
Top 10 Hldgs %
54.24%
Holding
331
New
77
Increased
88
Reduced
65
Closed
73

Top Buys

Rank Stock Value
1
FIVN icon
FIVE9
FIVN
+$41.6M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$39M
3
DPZ icon
Domino's
DPZ
+$33.2M
4
INCY icon
Incyte
INCY
+$27.6M
5
HUM icon
Humana
HUM
+$26.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$109M
2
EXAS
Exact Sciences
EXAS
+$59.2M
3
SNY icon
Sanofi
SNY
+$49.7M
4
KDP icon
Keurig Dr Pepper
KDP
+$49.6M
5
GSK icon
GSK
GSK
+$39.9M

Sector Composition

Rank Sector Weight
1 Healthcare 41.55%
2 Consumer Discretionary 7.13%
3 Consumer Staples 5.35%
4 Technology 5.24%
5 Communication Services 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KVUE icon
301
Kenvue
KVUE
$36.8B
– –
-1,588,358
Closed -$28.9M
LEXX icon
302
Lexaria Bioscience
LEXX
$8.82M
– –
-68,000
Closed -$2.84M
MTB icon
303
M&T Bank
MTB
$36.2B
– –
-1,512
Closed -$229K
NCEL
304
NewcelX Ltd
NCEL
$17.6M
– –
-5,778
Closed -$501K
NRSN icon
305
NeuroSense Therapeutics
NRSN
$18M
– –
-1,584,000
Closed -$1.77M
ONON icon
306
On Holding
ONON
$12.5B
– –
-12,811
Closed -$497K
PRFX icon
307
PRF Technologies Ltd
PRFX
$3.22M
– –
-2,300
Closed -$132K
ALP
308
Alpha Compute
ALP
$4.45M
– –
-75,089
Closed -$319K
PTN
309
Palatin Technologies
PTN
$14.3M
– –
-33,562
Closed -$3.27M
RHP icon
310
Ryman Hospitality Properties
RHP
$7.69B
– –
-60,063
Closed -$6M
RPM icon
311
RPM International
RPM
$14.9B
– –
-3,872
Closed -$417K
SGMO
312
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-14,060,000
Closed -$5.04M
SIG icon
313
Signet Jewelers
SIG
$3.72B
– –
-43,267
Closed -$3.88M
SJM icon
314
J.M. Smucker
SJM
$12.8B
– –
-3,377
Closed -$368K
SLGL icon
315
Sol-Gel Technologies
SLGL
$274M
– –
-203,200
Closed -$1.81M
DCOY
316
Decoy Therapeutics
DCOY
$2.09M
– –
-126
Closed -$54.1K
SNGX icon
317
Soligenix
SNGX
$5.8M
– –
-80,000
Closed -$206K
SONN
318
DELISTED
Sonnet BioTherapeutics
SONN
– –
-34,000
Closed -$255K
TARA icon
319
Protara Therapeutics
TARA
$228M
– –
-520,000
Closed -$1.08M
TXG icon
320
10x Genomics
TXG
$6.34B
– –
-154,482
Closed -$3M
VSXY
321
Victoria's Secret
VSXY
$7.78B
– –
-219,000
Closed -$3.87M
VTGN icon
322
VistaGen Therapeutics
VTGN
$12.9M
– –
-300,000
Closed -$1.04M
WATT icon
323
Energous
WATT
$103M
– –
-13,600
Closed -$445K
WST icon
324
West Pharmaceutical
WST
$24.9B
– –
-13,283
Closed -$4.38M
GRDX
325
GridAI Technologies Corp
GRDX
$19.6M
– –
-42,000
Closed -$155K
10 11 12
13
14

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Armistice Capital held 331 positions worth $6.25B, down 21% from $7.95B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Armistice Capital withdrew a net $2.08B in Q3 2024, closing 73 positions and reducing 65 holdings. Its most notable exit was Exact Sciences, an estimated $59.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 33% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

Against the trend, Armistice Capital opened a new position in Paramount Global Class B worth $21.2M.

  • Armistice Capital's largest Q3 2024 buy was Paramount Global Class B: 2,000,000 shares worth $21.2M.
  • Armistice Capital added most to FIVE9 in Q3 2024, an estimated $41.6M increase.
  • Armistice Capital's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $109M.
  • Armistice Capital fully exited Exact Sciences in Q3 2024, selling an estimated $59.2M.
  • Armistice Capital's ten largest holdings make up 54% of its $6.25B portfolio in Q3 2024.
  • Armistice Capital opened 77 new positions and closed 73 in Q3 2024.
  • Armistice Capital's portfolio value fell 21% quarter-over-quarter to $6.25B.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.